Released on: December 31, 2021
Deadline extended to: June 30, 2023
This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.
This activity is supported by an independent grant from Alexion Pharmaceuticals.
- Physicians— maximum of 0.75 AMA PRA Category 1 Credit(s)™
- Nurses— maximum of 0.75 contact hours of nursing continuing professional development (NCPD)
- Pharmacists– maximum of 0.75 contact hours of continuing pharmacy education credit
All other healthcare professionals completing this course will be issued a statement of participation.
Target AudienceThis activity is designed to meet the educational needs of neurologists, nursing professionals, PAs, pharmacists, and other healthcare professionals involved in the management of patients with neuromyelitis optica spectrum disorder (NMOSD).
Program OverviewThe enduring activity is designed to provide evidence-based education on the diagnosis of patients with NMOSD, evidence on novel treatments, and considerations in personalizing therapy.
Upon completion of this activity, participants should be better able to:
- Define signs and symptoms of NMOSD
- Review diagnostic testing methods for NMOSD
- Utilize consensus diagnostic criteria to support the diagnosis of NMOSD
- Review mechanisms of action of novel targeted therapies for NMOSD
- Apply evidence on novel therapies to the treatment of patients with NMOSD
Dean Wingerchuk, MD, MSc, FRCP(C)
Professor and Chair
Department of Neurology